UA80393C2 - Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці - Google Patents

Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці Download PDF

Info

Publication number
UA80393C2
UA80393C2 UA2003076286A UA2003076286A UA80393C2 UA 80393 C2 UA80393 C2 UA 80393C2 UA 2003076286 A UA2003076286 A UA 2003076286A UA 2003076286 A UA2003076286 A UA 2003076286A UA 80393 C2 UA80393 C2 UA 80393C2
Authority
UA
Ukraine
Prior art keywords
sodium
acid
composition according
droplets
excipients
Prior art date
Application number
UA2003076286A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Ранго Дітріх
Рудольф Ліндер
Хартмут Ней
Original Assignee
Алтана Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алтана Фарма Аг filed Critical Алтана Фарма Аг
Publication of UA80393C2 publication Critical patent/UA80393C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UA2003076286A 2000-12-07 2001-06-12 Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці UA80393C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126847 2000-12-07
PCT/EP2001/014307 WO2002045693A1 (en) 2000-12-07 2001-12-06 Pharmaceutical preparation comprising an active dispersed on a matrix

Publications (1)

Publication Number Publication Date
UA80393C2 true UA80393C2 (uk) 2007-09-25

Family

ID=8170601

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003076286A UA80393C2 (uk) 2000-12-07 2001-06-12 Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Country Status (28)

Country Link
US (2) US7175854B2 (de)
EP (1) EP1341527B1 (de)
JP (1) JP4950409B2 (de)
KR (1) KR20030072557A (de)
CN (2) CN101810592A (de)
AT (1) ATE519481T1 (de)
AU (2) AU2002216073B2 (de)
BR (1) BR0115987A (de)
CA (1) CA2430828C (de)
CY (1) CY1112333T1 (de)
CZ (1) CZ20031881A3 (de)
DK (1) DK1341527T3 (de)
EA (1) EA007151B1 (de)
EE (1) EE05256B1 (de)
ES (1) ES2371060T3 (de)
HR (1) HRP20030493B1 (de)
HU (1) HUP0400566A3 (de)
IL (2) IL155964A0 (de)
MX (1) MXPA03005092A (de)
NO (1) NO333722B1 (de)
NZ (1) NZ526015A (de)
PL (1) PL206595B1 (de)
PT (1) PT1341527E (de)
SG (1) SG148028A1 (de)
SI (1) SI1341527T1 (de)
UA (1) UA80393C2 (de)
WO (1) WO2002045693A1 (de)
ZA (1) ZA200305114B (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
SI1341524T1 (sl) * 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2004002466A1 (en) * 2002-06-28 2004-01-08 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
KR101016595B1 (ko) 2002-07-31 2011-02-22 센주 세이야꾸 가부시키가이샤 수성액제 및 광안정화된 수성액제
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
AR045142A1 (es) * 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
US7955620B2 (en) * 2003-12-23 2011-06-07 Sun Pharmaceutical Industries Limited Stable oral composition
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
KR100681660B1 (ko) * 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
EP1579862A1 (de) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
CN100345544C (zh) * 2004-06-10 2007-10-31 范敏华 一种尼麦角林口腔崩解片剂及其制备方法
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
AU2005291302A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
KR100706036B1 (ko) * 2005-04-04 2007-04-11 대화제약 주식회사 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Pde5インヒビターの迅速吸収性経口処方物
JP2009501722A (ja) * 2005-07-15 2009-01-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ドロスピレノン含有経皮用薬剤供給装置及びその供給方法
EP1762179A1 (de) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Methode zur Verbesserung der Qualität der Diagnostik in der Echokardiographie
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
DE202006020168U1 (de) * 2005-12-21 2008-07-17 Basf Se Pharmazeutische Formulierung für die Herstellung von schnell zerfallenden Tabletten
JP2007210905A (ja) * 2006-02-07 2007-08-23 Asahi Breweries Ltd 口腔内用顆粒、錠剤およびその製造方法
CN1915233B (zh) * 2006-08-30 2012-10-03 四川科瑞德制药有限公司 一种治疗焦虑症的药物组合物及其口崩制剂
WO2008031928A1 (fr) * 2006-09-14 2008-03-20 Pierre Fabre Medicament Utilisation du milnacipran pour diminuer les proprietes recompensantes de l'alcool pendant ou apres un traitement de sevrage alcoolique
EP1920785A1 (de) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
KR100815029B1 (ko) * 2006-11-29 2008-03-18 부광약품 주식회사 독소필린 서방출성 제제
US20100104656A1 (en) * 2007-03-20 2010-04-29 Paul Wan Sia Heng Meltable Binder for Melt Granulation and/or Pelletization
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
AU2008262438A1 (en) * 2007-06-07 2008-12-18 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
EP2240173A4 (de) * 2008-01-25 2013-07-17 Alphapharm Pty Ltd Pharmazeutische zusammensetzung von duloxetin mit verzögerter freisetzung
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
EP2393827B1 (de) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Neue prodrugs von steroiden cyp17-inhibitoren/antiandrogenen
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
UA102070C2 (uk) * 2009-12-16 2013-06-10 Общество С Ограниченной Ответственностью "Фармацевтическая Группа "Здоровье" Застосування фармацевтичної композиції, що містить (s)-2-аміно-5-гуанідинопентанової кислоти (s)-2-аміноглутарат, для лікування і профілактики патологій вагітності
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
US8900605B2 (en) * 2010-06-14 2014-12-02 Ratiopharm Gmbh Solid ivabradine-containing composition
CN101879139A (zh) * 2010-06-23 2010-11-10 广西方略药业集团有限公司 一种治疗消化性疾病的肠溶制剂及其制备方法
CN102309442A (zh) * 2010-07-07 2012-01-11 澳美制药厂 盐酸氨溴索口服水性组合物及其制备方法
CN102309460B (zh) * 2010-07-09 2013-04-24 重庆医科大学 溴吡斯的明掩味口腔崩解片及其制备方法
EP2543364A1 (de) * 2010-10-14 2013-01-09 Deva Holding Anonim Sirketi Formulierungen von Cetylmyristat und/oder Cetylpalmitat
FR2967067A1 (fr) * 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
RU2482847C2 (ru) * 2010-11-17 2013-05-27 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая силденафил или алпростадил, миноксидил или эуфиллин, тестостерон или йохимбин и липосомы для местного применения
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ,インク. 前立腺癌を処置するための新規な組成物及び方法
US9730913B2 (en) * 2011-10-13 2017-08-15 The Johns Hopkins University High affinity beta lactamase inhibitors
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9717678B2 (en) * 2011-11-06 2017-08-01 Murty Pharmaceuticals, Inc. Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN104736152B (zh) * 2012-08-13 2018-01-23 阿迪帕姆单人股份公司 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法
CN102988297A (zh) * 2012-12-21 2013-03-27 无锡泓兴生物医药科技有限公司 罗氟司特固体分散体及含有其的药物组合物
CN110464724A (zh) * 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
MX376094B (es) 2013-07-11 2025-03-07 Talsy Pharmaceutical Group Co Ltd Composición de medicina china tradicional, y preparación y aplicación de la misma.
WO2015003661A1 (zh) 2013-07-11 2015-01-15 天士力制药集团股份有限公司 一种中药微滴丸的制备方法以及由所述方法制得的中药微滴丸
ES3034682T3 (en) 2013-07-11 2025-08-21 Tasly Pharmaceutical Group Co Traditional chinese medicine composition, and preparation and application thereof
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
KR101399514B1 (ko) * 2013-10-28 2014-05-27 에스케이케미칼주식회사 폴라프레징크를 함유하는 안정한 정제 제형
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
WO2015132708A1 (en) * 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
CN104434811A (zh) * 2014-11-07 2015-03-25 浙江大学 一种可嵌于人工晶状体襻上的药物缓释微球及其制备方法
US9710054B2 (en) 2015-02-28 2017-07-18 Intel Corporation Programmable power management agent
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN109432039B (zh) * 2015-06-03 2021-06-22 南京三迭纪医药科技有限公司 药品剂型及其使用
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
WO2017160106A2 (ko) 2016-03-16 2017-09-21 한미약품 주식회사 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3308773A1 (de) 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulierungen von cysteamin und cysteaminderivaten
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019059652A1 (ko) * 2017-09-19 2019-03-28 경상대학교 산학협력단 맛이 차폐된 경구투여용 약학적 제제 및 이의 제조 방법
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CN110051633A (zh) * 2018-11-27 2019-07-26 宁夏医科大学 一种环维黄杨星d纳米制剂及其制备方法
CN111840308B (zh) * 2019-07-18 2022-03-01 北京市农林科学院 6种小分子药物在抑制犬细小病毒中的应用
CN111000844B (zh) * 2019-12-19 2022-06-28 浙江立恩生物科技有限公司 一种治疗流感病毒感染的药物
CN115209876A (zh) * 2020-03-11 2022-10-18 泽井制药株式会社 颗粒和使用该颗粒的制剂
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
CN112546000B (zh) * 2020-12-30 2023-06-20 海南海神同洲制药有限公司 一种盐酸克林霉素棕榈酸酯干混悬剂及其制备方法
CN113662920A (zh) * 2021-09-28 2021-11-19 南京长澳医药科技有限公司 一种比拉斯汀口腔崩解片及其制备方法
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
CN114796127B (zh) * 2022-05-16 2025-03-07 北京斯利安药业有限公司 伊来西胺缓释干混悬剂及其制备方法
IL319352A (en) 2022-09-15 2025-05-01 Arcutis Biotherapeutics Inc Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug
CN121154557B (zh) * 2025-11-21 2026-01-30 内蒙古鸿信达生物药业有限公司 一种含地克珠利的复方抗球虫制剂制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
EP0068378B1 (de) 1981-06-26 1986-03-05 Schering Corporation Imidazo(1,2-a)pyridine und -pyrazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
GB8415540D0 (en) 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS625966A (ja) 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (de) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridinverbindungen und Verfahren zu ihrer Herstellung
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
NZ221996A (en) 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
EP0264883A3 (de) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituierte Pyridinderivate
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
EP0370056A1 (de) 1987-07-16 1990-05-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazole
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
EP0368158A1 (de) 1988-11-07 1990-05-16 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Imidazopyridine
JPH02270873A (ja) 1989-03-13 1990-11-05 Fujisawa Pharmaceut Co Ltd イミダゾピリジン化合物およびその製造法
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
JPH0331280A (ja) 1989-06-28 1991-02-12 Fujisawa Pharmaceut Co Ltd 新規イミダゾピリジン化合物
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DE69128682T2 (de) 1990-03-28 1998-06-04 Otsuka Pharma Co Ltd Chinolinderivat, antiulcus-mittel das dieses derivat enthält und darstellung dieses derivates
JP2851117B2 (ja) 1990-03-30 1999-01-27 日清製粉株式会社 インドール誘導体およびそれらを有効成分とする抗潰瘍薬
JP2816227B2 (ja) 1990-03-30 1998-10-27 日清製粉株式会社 抗潰瘍薬
PT97467A (pt) 1990-04-27 1992-01-31 Byk Gulden Lomberg Chem Fab Processo para preparacao de novas piridazinas e de composicoes farmaceuticas que as contem
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (de) 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazine
SK70993A3 (en) 1991-01-29 1994-01-12 Smithkline Beecham Intercredit Salts of 4-amino-3-acylquionoline derivative and their use as inhibitors of gastric acid secretion
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
ES2202302T3 (es) * 1991-05-28 2004-04-01 Mcneil-Ppc, Inc. Composicion masticable que libera un farmaco.
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
ATE179419T1 (de) 1991-10-25 1999-05-15 Byk Gulden Lomberg Chem Fab Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
GB9126438D0 (en) 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JP3523275B2 (ja) 1992-03-26 2004-04-26 東光薬品工業株式会社 貼付剤
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0695303B1 (de) 1993-04-22 2001-11-28 Byk Gulden Lomberg Chemische Fabrik GmbH Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
US5556863A (en) 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
SE9401197D0 (sv) 1994-04-11 1994-04-11 Astra Ab Active compounds
CN1046726C (zh) 1994-07-28 1999-11-24 比克·古尔顿·劳姆贝尔格化学公司 咪唑并吡啶-吡咯烷酮、其制法和药用
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
US5677302A (en) * 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
CA2289542A1 (en) 1997-05-28 1998-12-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Fused dihydropyrans
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
HUP0001555A3 (en) 1997-10-30 2001-01-29 Altana Pharma Ag Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
JP4370429B2 (ja) 1998-09-10 2009-11-25 東和薬品株式会社 徐放性マイクロスフエアの製造法
WO2000017200A1 (en) 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers
CA2349476A1 (en) 1998-11-03 2000-05-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazonaphthyridines
AU3966600A (en) 1999-04-17 2000-11-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Haloalkoxy imidazonaphthyridines
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
EE200100660A (et) * 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002045694A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient

Also Published As

Publication number Publication date
NO333722B1 (no) 2013-09-02
BR0115987A (pt) 2003-12-23
HRP20030493A2 (en) 2005-06-30
KR20030072557A (ko) 2003-09-15
EA007151B1 (ru) 2006-08-25
EP1341527A1 (de) 2003-09-10
PT1341527E (pt) 2011-10-04
AU2002216073B2 (en) 2006-11-23
EP1341527B1 (de) 2011-08-10
AU1607302A (en) 2002-06-18
WO2002045693A1 (en) 2002-06-13
ZA200305114B (en) 2004-05-12
HRP20030493B1 (hr) 2011-10-31
NO20032593L (no) 2003-08-05
CN1523980A (zh) 2004-08-25
DK1341527T3 (da) 2011-10-24
CA2430828A1 (en) 2002-06-13
ES2371060T3 (es) 2011-12-27
ATE519481T1 (de) 2011-08-15
MXPA03005092A (es) 2003-09-05
JP2004514736A (ja) 2004-05-20
PL362323A1 (en) 2004-10-18
EA200300634A1 (ru) 2003-12-25
CZ20031881A3 (en) 2004-04-14
US20040058896A1 (en) 2004-03-25
PL206595B1 (pl) 2010-08-31
NO20032593D0 (no) 2003-06-06
JP4950409B2 (ja) 2012-06-13
EE200300235A (et) 2003-08-15
US7175854B2 (en) 2007-02-13
IL155964A (en) 2012-06-28
IL155964A0 (en) 2003-12-23
NZ526015A (en) 2006-03-31
SG148028A1 (en) 2008-12-31
US20070122474A1 (en) 2007-05-31
HUP0400566A3 (en) 2012-09-28
CA2430828C (en) 2010-11-09
SI1341527T1 (sl) 2011-12-30
CY1112333T1 (el) 2015-12-09
CN101810592A (zh) 2010-08-25
US7951398B2 (en) 2011-05-31
HUP0400566A2 (hu) 2004-06-28
EE05256B1 (et) 2010-02-15

Similar Documents

Publication Publication Date Title
US7951398B2 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
AU2002216073A1 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
US7976871B2 (en) Modified release composition of highly soluble drugs
US8268352B2 (en) Modified release composition for highly soluble drugs
CN103271083B (zh) 多功能离子液体组合物
US8263125B2 (en) Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US9308181B2 (en) Topical formulations, systems and methods
US20170319698A1 (en) Gastroretentive gel formulations
EP4706683A2 (de) Kaubare formulierungen
US20230059204A1 (en) Transdermal micro-dosing delivery of pharmaceutical agents
BR112021004053A2 (pt) composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos
JP2000514405A (ja) Dha―薬剤複合体
KR20220126287A (ko) 멀티모달 조성물 및 치료 방법
DE10061137A1 (de) Neue pharmazeutische Zubereitung